Age: 0.18
Sex: F
Vaccine: HEP, HIBV, DTAP, HIBV, MMR
Symptoms: Neurodevelopmental disorder, Oliguria, Sinusitis, Sleep disorder, Speech disorder
Clinical narrative: Information has been received regarding a case in litigation concerning a minor male patient who was exposed to high levels of mercury from thimerosal through exposure to unspecified products. In addition the patient was exposed to mercury from continually inhaling and ingesting mercury emissions from fossil fuel driven power plants. The mercury included in thimerosal laden products and power plant emissions together caused the patient to suffer from serious and permanent neurological injuries. The patient was exposed to airborne mercury vapor and mercury through food chain. The exposure to airborne mercury in the environment through inhalation, the food chain, and other sources contributed to the cumulative mercury toxicity and was a substantial factor in causing his neurological damage. It was noted that the patient had a heightened vulnerability to suffer neurological injuries from industrial mercury as a direct result of thimerosal exposure. As a direct and proximate cause of the toxic mercury exposure to the patient, minor male was caused to suffer serious and permanent neurological damage which included past and future mental, intellectual, developmental and neurological incapacity and associated learning disabilities. Upon internal review, serious and permanent neurological damage/injuries which include past and future mental, intellectual, developmental and neurological incapacity and associated learning disabilities, disorders and impairments and cumulative mercury toxicity were considered to be other important medical events (OMIC).  Additional information has been received from medical records on 14-SEP-2006, regarding a case in litigation concerning a minor patient with allergy to penicillin, Keflex, and Zithromax and a history of hives, who on 11-JUL-1994, 08-AUG-1994 and 02-DEC-1994 was vaccinated with hepatitis B virus vaccine rHBsAg (yeast) (manufacturer unknown). On 06-NOV-1994, the patient was hospitalized for bronchiolitis and was discharged from the hospital on 08-NOV-1994. On 14-SEP-1995, the patient was vaccinated with secondary suspect MMRII. On 09-DEC-1996, the patient was vaccinated with secondary suspect varicella virus vaccine live, and in 02-JUN-1998, the patient was vaccinated with a second dose of MMRII (lot # 621993/0026H). Concomitant therapy included therapy unspecified, Infanrix, ActHIB, Tetramune, Pediarix, oxygen, Ritalin and clonidine. On 13-DEC-1995, the physician reported the patient had delays in communication and social interaction. On 10-FEB-1997, it was reported again that the patient's communication skills were delayed and added that the patient appeared socially distant. On 15-SEP-1997, the physician noted the patient was failure to thrive. On 21-AUG-1998, the physician noted that the patient had two previous hospitalizations. It was noted by a physician that the patient had been treated for medical diagnosis of Attention Deficit Disorder since November 1998. On 15-FEB-2000, it was noted that the patient received services under the disabling condition of "speech and language" impairment. On 12-APR-2000, the patient was diagnosed with Asperger's Disorder. On 21-APR-2000, it was noted the patient had Atypical Autism, which was considered an educational disability. Follow-up information received on 12-SEP-2006, contained the following adverse experiences; contact dermatitis (25-JUL-1994), runny nose (25-JUL-1994), chronic sinusitis, sleep disorder, vomiting, decreased urine output (26-APR-1997), headache (16-JUN-2000). Upon internal review it was considered that pervasive developmental disorder/atypical autism was an important medical event (OMIC). Additional information has been requested. All available medical records will be provided upon request.